Email Updates

You are here

HVTN 702 and the Quest for Vaccine

March 10, 2020

Px Pulse Logo

One of the most anticipated HIV vaccine efficacy trials in the field—HVTN 702, or Uhambo—stopped vaccinations early after a scheduled review showed the vaccine did not offer protection. The news delivered disappointment to the more than 5,000 South Africans who participated in the study, local communities, the field worldwide.

The trial team will continue to follow participants over the next year to monitor safety and answer urgent questions raised by the trial results. In this episode of Px Pulse, HVTN 702 Protocol Co-chair and AVAC Board Member Linda-Gail Bekker explores what the trial team hopes to learn during the follow-up period and how these answers might impact the ongoing pursuit for an HIV vaccine. AVAC’s Regional Stakeholder Engagement Advisor Nandisile Luthuli also joins the conversation to shed light on the trial team’s plans for continuing community engagement, and AVAC’s Director of Research Engagement, Stacey Hannah, talks about the successes of the trial.




Additional Resources